Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Merck & Co Inc (NYSE:MRK)

49.53
Delayed Data
As of Feb 10
 +0.37 / +0.75%
Today’s Change
45.69
Today|||52-Week Range
61.70
-6.23%
Year-to-Date
Stock Market News for February 10, 2016
Feb 10 / Zacks.com
Why Medivation, Inc. Shares Crashed 32% in January
Feb 03 / MotleyFool.com
3 Biotech Stocks to Buy in a Market Crash
Feb 09 / MotleyFool.com
Can Perrigo (PRGO) Beat Q4 Earnings on Generic Sales?
Feb 02 / Zacks.com
Pfizer Gets Back to Growth
Feb 09 / MotleyFool.com
Why Gilead Sciences Shares Tumbled 18% in January
Feb 02 / MotleyFool.com
Curing Hepatitis C: How Gilead Sciences Plans to Beat Merck
Feb 09 / MotleyFool.com
Should You Buy Merck (MRK) Ahead of Earnings?
Feb 02 / Zacks.com
1 Chart That's Bringing Big Smiles to America's Largest Companies
Feb 09 / MotleyFool.com
Will Merck (MRK) Keep the Earnings Streak Alive in Q4?
Feb 01 / Zacks.com
Bristol-Myers' Daklinza-Sovaldi Label Expanded by the FDA
Feb 08 / Zacks.com
Is Alexion (ALXN) Likely to Disappoint this Earnings Season?
Feb 01 / Zacks.com
AstraZeneca cancer drug presents breakthrough
Feb 07 / FT.com
3 Numbers That Matter When Merck Reports Its Fourth-Quarter Results
Feb 01 / MotleyFool.com
Waging War on the Greatest Cancer Myth of All
Feb 07 / MotleyFool.com
GW Pharmaceuticals (GWPH): What Awaits in Q1 Earnings?
Feb 01 / Zacks.com
Is Gilead Sciences Finally Nearing a Bottom?
Feb 07 / MotleyFool.com
Investor calls for big pharma to slim down grow louder
Feb 01 / FT.com
Last Week's Best Healthcare ETF
Feb 06 / MotleyFool.com
Will 2016 Be Merck & Co. Inc.'s Best Year Yet?
Feb 01 / MotleyFool.com
Grading Gilead Sciences' Performance in 2015
Feb 06 / MotleyFool.com
Biotech ETFs Hit 52-Week Lows: Time to Buy?
Feb 01 / Zacks.com
1 Company Gilead Sciences Should Consider Buying Right Now
Feb 06 / MotleyFool.com
Gilead risks becoming victim of its own success
Jan 31 / FT.com
ImmunoGen/Merck Collaborate for Ovarian Cancer Study
Feb 05 / Zacks.com
Merck's HCV Drug Zepatier Gets FDA Nod; Sets Lower Price
Jan 29 / Zacks.com
Amgen's Blincyto and Repatha Positive in Phase III Studies
Feb 05 / Zacks.com
Instant Analysis: Gilead Sciences Inc.'s Longtime CEO Steps Down
Jan 29 / MotleyFool.com
Gilead Sciences 2016 Guidance: Sandbagging Wall Street Again?
Feb 05 / MotleyFool.com
Why is Gilead (GILD) Stock Falling Today?
Jan 29 / Zacks.com
Dow 30 Stock Roundup: Microsoft, Exxon Beat on Earnings, Chevron Incurs Loss
Feb 05 / Zacks.com
Will Pfizer (PFE) Keep the Earnings Streak Alive in Q4?
Jan 29 / Zacks.com
String of Q4 Earnings Beat Fails to Revive Pharma ETFs
Feb 05 / Zacks.com
Merck launches hepatitis C drug price war
Jan 29 / FT.com
5 Stocks We're Buying Again
Feb 05 / MotleyFool.com
Instant Analysis: Can Merck Make Waves In the Crowded Hepatitis C Space?
Jan 29 / MotleyFool.com
2 Numbers in Merck's 4th-Quarter Report That Have Investors Worried
Feb 04 / MotleyFool.com
Merck's Hepatitis C Doublet Wins FDA Approval and Unveils Its Secret Weapon
Jan 29 / MotleyFool.com
Company News for February 04, 2016
Feb 04 / Zacks.com
CDXS and LOGI are Aggressive Growth Stocks
Jan 28 / Zacks.com
Hedge fund pioneer is force behind hotly tipped biotech companies
Feb 04 / FT.com
Johnson & Johnson's Newest Billion-Dollar Blockbuster
Jan 28 / MotleyFool.com
International Growth Propels Gilead Sciences Inc.'s Solid Q4 Results
Feb 03 / MotleyFool.com
England backs biosimilar challenger to Merck blockbuster
Jan 26 / FT.com
Merck Tops on Q4 Earnings, Revenue Outlook Falls Short
Feb 03 / Zacks.com
Brexit would be a 'mistake', say global pharma leaders
Jan 24 / FT.com
Gilead (GILD) Beats Q4 Earnings Estimates, Gives 2016 View
Feb 03 / Zacks.com
Drugmakers call for collective action on superbugs
Jan 20 / FT.com
Merck's (MRK) Q4 Earnings Beat Estimates
Feb 03 / Zacks.com
Merck of Germany wins UK support in battle with US namesake
Jan 15 / FT.com